Author: OurCrowd

[Edity Therapeutics in WebWire] Edity Therapeutics enters into a strategic collaboration with Dr. Reddy’s Laboratories to advance novel cell therapy approach using Edity’s proprietary delivery platform

Jan 16, 2024 |

Edity Therapeutics announced a strategic collaboration with Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) to create novel cell therapy medicines by applying Edity’s proprietary delivery platform. Read...

Read More

[ProFuse in PR Newswire] ProFuse Technology revolutionizes skeletal muscle research with groundbreaking media supplement, PROFUSE-S1

Jan 16, 2024 |

r KIRYAT SHMONA, Israel, Jan. 16, 2024 /PRNewswire/ — ProFuse Technology, a leader in innovative solutions for life science research, today announced the launch of PROFUSE-S1, a groundbreaking media supplement specifically engineered to accelerate and enhance skeletal muscle research across academic, cultivated meat, and life science sectors. Read more...

Read More

[Corelight in PR Newswire] Corelight expands partnership with Amazon Web Services (AWS) to provide cloud security solutions to customers worldwide

Jan 16, 2024 |

SAN FRANCISCO, Jan. 16, 2024 /PRNewswire/ — Corelight, the leader in open network detection and response (NDR), today announced that it has been accepted into the Amazon Web Services (AWS) Independent Software Vendor (ISV) Accelerate Program. This co-sell program for AWS Partners facilitates software solutions that run on or integrate with AWS, helping AWS partners drive new business and accelerate sales cycles by connecting participating ISVs with the AWS sales organization. Read...

Read More